Violini V, Romanello A, Vannetti A, Alasino M, Copparoni C, Samper A, Papailiou MP

Idioma: Español
Referencias bibliográficas: 13
Paginas: 147-150
Archivo PDF: 253.00 Kb.

RESUMEN

El síndrome del shock tóxico estreptocócico es causado por el estreptococo del grupo A (pyogenes). El rol principal en la patogenia son los superantígenos, que junto a otros factores de virulencia del estreptococo del grupo A (SGA), antecedente de lesión del tejido blando y liberación de citoquinas, son capaces de desarrollar esta infección con elevada mortalidad. Se presenta el caso de un paciente de 47 años de edad, sin antecedentes patológicos, que consulta a la guardia de nuestro nosocomio por malestar general con vómitos y diarrea de 72 horas de evolución, con aparición de placas pardonegruzcas con ampollas serohemáticas en su superficie y áreas denudadas, falleciendo en menos de 16 horas en la unidad de cuidados intensivos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Martin PR, Høiby EA. Streptococcal serogroup A epidemic in Norway 1987-1988. Scandinavian Journal of Infectious Diseases. 1990; 22 (4): 421-429.

2. Stevens DL, Bryant AE. Severe group A streptococcal infections. In: Ferretti JJ, Stevens DL, Fischetti VA. Streptococcus pyogenes: basic biology to clinical manifestations. Oklahoma City: 2016. pp. 741-769.

3. DiPersio JR, File TM, Stevens DL, Gardner WG, Petropoulos G, Dinsa K. Spread of serious disease-producing M3 clones of group A Streptococcus among family members and health care workers. Clinical Infectious Diseases. 1996; 22 (3): 490-495.

4. Herold AH. Group A beta-hemolytic streptococcal toxic shock from a mild pharyngitis. The Journal of Family Practice. 1990; 31 (5): 549-551.

5. Barnham M. Nonsteroidal antiinflammatory drugs: concurrent or causative drugs in serious infection? Clinical Infectious Diseases. 1997; 25 (5): 1272-1273.

6. Lancefield RC. A serological differentiation of human and other groups of hemolytic streptococci. The Journal of Experimental Medicine. 1933; 57 (4): 571-595.

7. Bryant AE, Bayer CR, Huntington JD, Stevens DL. Group A streptococcal myonecrosis: increased vimentin expression after skeletal-muscle injury mediates the binding of Streptococcus pyogenes. The Journal of Infectious Diseases. 2006; 193 (12): 1685-1692.

8. Norrby-Teglund A, Basma H, Andersson J, McGeer A, Low DE, Kotb M. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clinical Infectious Diseases. 1998; 26 (3): 631-638.

9. Stevens DL, Bryant AE, Hackett SP, Chang A, Peer G, Kosanke S et al. Group A streptococcal bacteremia: the role of tumor necrosis factor in shock and organ failure. The Journal of Infectious Diseases. 1996; 173 (3): 619-626.

10. Stevens DL, Tanner MH, Winship J, Swarts R, Reis KM, Schlievert PM et al. Reappearance of scarlet fever toxin A among streptococci in the Rocky Mountain West: severe group A streptococcal infections associated with a toxic shock-like syndrome. The New England Journal of Medicine. 1989; 321 (1): 1-7.

11. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2014; 59 (2): e10-e52.

12. Proft T, Fraser JD. Streptococcal superantigens: biological properties and potential role in disease. In: Ferretti JJ, Stevens DL, Fischetti VA. Streptococcus pyogenes: basic biology to clinical manifestations. Oklahoma City: 2016. pp. 1-32.

13. Young K, Khan Luni F, Yoon Y. Toxic shock syndrome an unusual organism. Am J Med Sci. 2016; 352 (1): 86-90.